Clinical Trial Update: Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating daily interleukin-2 for steroid-refractory chronic graft-versus-host disease; results were posted on 2015-01-15.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Interleukin-2 (interleukin-2)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Chronic Graft-versus-host Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2015-01-15